NSRX סך נכסי הפעילות העסקית Nasus Pharma, Ltd.

Nasus Pharma Ltd (NSRX) wields significant influence in the emergency therapy segment due to its unique drug delivery method. The company is developing innovative Taffix nasal sprays that create a protective viral barrier for the immediate termination of attacks. Production is being modernized through the implementation of robotic manipulators in sterile zones for the precise filling of nanocomponents. Total assets amount to 2.18, which clearly demonstrates the price trend reflected below.

Identifying a fundamental floor for Nasus Pharma Ltd (NSRX) requires an analysis of the company's total assets, which are reverse-calculated via ROA to assess the aggregate of equity and debt capital. This trend captures the scale of resources necessary to develop nasal delivery systems and complete regulatory testing, determining the business's financial stability as it transitions to mass pharmacy sales.